175213-46-4

Basic information

• Product Name: METHYL 1-BOC-4-PIPERIDINEACETATE
• Synonyms: N-BOC-4-PIPERIDINEACETIC ACID METHYL ESTER;METHYL 1-BOC-4-PIPERIDINEACETATE;t-Butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate;Methyl N-Boc-4-piperidineacetate Methyl 1-Boc-4-piperidineacetate 4-((Methoxycarbonyl)methyl)piperidine-1-carboxylic acid tert-butyl ester;tert-butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate;1-Boc-4-Piperidine acetate methyl ester;1-Boc-4-Piperidine acetic acid methyl ester;Methyl 1-N-Boc-4-piperidineacetate
• CAS NO: 175213-46-4
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.33
• Product Categories: Amines;blocks;Carboxes;pharmacetical
• Mol File: 175213-46-4.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 323.1 °C at 760 mmHg
• Flash Point: 149.2 °C
• Appearance: /
• Density: 1.062 g/cm³
• Vapor Pressure: 0.000267mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.88±0.40(Predicted)
• CAS DataBase Reference: METHYL 1-BOC-4-PIPERIDINEACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 1-BOC-4-PIPERIDINEACETATE(175213-46-4)
• EPA Substance Registry System: METHYL 1-BOC-4-PIPERIDINEACETATE(175213-46-4)

Safety Data

• Hazardous Substances Data: 175213-46-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C13H23NO4/c1-13(2,3)18-12(16)14-7-5-10(6-8-14)9-11(15)17-4/h10H,5-9H2,1-4H3

Upstream product

• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 169206-65-9 1-tert-butoxycarbonyl-4-[(methoxycarbonyl)methylene]piperidine 
• 7440-44-0 pyrographite 
• 7440-05-3 palladium 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 865-33-8 potassium methanolate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 81270-37-3 methyl piperidine-4-acetate hydrochloride 
• 168986-49-0 4-piperidine acetic acid methyl ester 
• 67-56-1 methanol 

Downstream Products

• 81270-37-3 methyl piperidine-4-acetate hydrochloride 
• 183170-69-6 1-tert-Butyloxycarbonyl-4-hydroxyethyl-piperidine 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 1103310-87-7 4-[3-(4-methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 865627-01-6 tert-butyl 4-(1-(3-fluoro-2-pivalamidophenyl)-1-hydroxy-3-methoxy-3-oxopropan-2-yl)piperidine-1-carboxylate 
• 1337918-84-9 4-[2-hydroxy-1-methoxycarbonyl-2-(2-nitro-phenyl)-ethyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1380344-31-9 C₂₁H₃₀N₄O 
• 1352428-49-9 C₃₀H₃₆N₄O₂ 
• 1352428-50-2 C₃₀H₃₈N₄O₂ 
• 1352428-52-4 C₂₉H₃₆N₄O₂ 
• 1352428-53-5 C₂₈H₃₄N₄O₂ 
• 1352428-54-6 C₂₈H₃₅N₅O₂ 
• 1352428-56-8 C₃₀H₃₅FN₄O₂ 
• 1352428-57-9 C₃₀H₃₅FN₄O₂ 

Relevant articles and documents

Oxidative esterification of alcohols by a single-side organically decorated Anderson-type chrome-based catalyst

The direct esterification of alcohols with non-noble metal-based catalytic systems faces great challenges. Here, we report a new chrome-based catalyst stabilized by a single pentaerythritol decorated Anderson-type polyoxometalate, [N(C4H9)4]3[CrMo6O18(OH)3C{(OCH2)3CH2OH}], which can realize the efficient transformation from alcohols to esters by H2O2oxidation in good yields and high selectivity without extra organic ligands. A variety of alcohols with different functionalities including some natural products and pharmaceutical intermediates are tolerated in this system. The chrome-based catalyst can be recycled several times and still keep the original configuration and catalytic activity. We also propose a reasonable catalytic mechanism and prove the potential for industrial applications.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ( BTK ) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.